NLS Other Current Assets from 2010 to 2024

NLSPW Stock  USD 0.02  0.0001  0.62%   
NLS Pharmaceutics Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets are likely to outpace its year average in 2024. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2010-12-31
Previous Quarter
925.4 K
Current Value
971.7 K
Quarterly Volatility
302.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of NLS Pharmaceutics AG over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. NLS Pharmaceutics' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

NLS Other Current Assets Regression Statistics

Arithmetic Mean219,395
Geometric Mean123,648
Coefficient Of Variation137.86
Mean Deviation204,107
Median90,867
Standard Deviation302,465
Sample Variance91.5B
Range957.2K
R-Value0.65
Mean Square Error57.4B
R-Squared0.42
Significance0.01
Slope43,683
Total Sum of Squares1.3T

NLS Other Current Assets History

2024971.7 K
2023925.4 K
2022191 K
2021292 K
202014.4 K
201986.1 K
201883.5 K

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Assets925.4 K971.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.